News Desk — May 18, 2018 at 8:16 am — Updated: May 18, 2018 at 8:16 am

AstraZeneca hit by falling Crestor sales, shares fall

by

LONDON (Reuters) – AstraZeneca’s first quarter profit was hit by generic competition to cholesterol fighter Crestor and higher costs, but the drugmaker expects a better second half and said it remained on track for a promised return to sales growth in 2018.

Leave A Comment Using Facebook (Website Comment Form Below)

Use the form below to post a comment via facebook

Leave a Reply

70 queries in 1.018 seconds.